Genmab — Marts 2018

[bibob]

Den har endnu ikke nået Børsen.

[JKY_VH]

Rigtigt bibob, det er fra Reuter. Foreløbig er vi kommet godt fra start med næsten + 3%

[bibob]

Det må da gerne holde og helst bedre til luk.

[JKY_VH]

Helt enig:-)

[Helge_LarsenPI-redaktør]

Har tippet Børsen om opjusteringen. De er lavt bemandet pga påsken.

[polle1]

Tak Helge, den er på Børsen nu (9.30)

[JKY_VH]

Tak Helge:-)

[Helge_LarsenPI-redaktør]

301 Moved Permanently

(penge.borsen.dk)

[Helge_LarsenPI-redaktør]

Selv tak JKY. Du var først.

[E_L]

am i correct in thinking that the pelvis would fall under the area bladder cancer?

[E_L]

New: Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma NCT03477539 - https://clinicaltrials.gov/ct2/show/NCT03477539

[E_L]

Phase 2, transplant + Dara + Lenalidomide, short study, only 1 year

[Bulder]

yesterday 20:23

[E_L]

oeps...uhm... well, yes, offcourse i saw that, i just wanted to re-emphasise it,,,

[Bulder]

sure, it's an important study. They now use MRDneg measuring in stead of PFS as primary outcome, which make the study-time much shorter. And secondly they make a "light" version out of the transplant setting. To see if dara alone as pre-treatment is enough, and if dara+len as maintemance is enough.

[E_L]

ok that clarifies. Was GRIFFIN with or without transplant?

[Bulder]

Griffin is the large two arm asct-study that compares SOC with and without dara. I would guess that they (Janssen) will apply for approval even though it's only a phase 2 study.

[E_L]

yes, ok, that is why i thought of the comparison with this study, which is only with Lenalidomide; is that why you called it "light" version ?

[Bulder]

yes and notably without dex - it seems. Many patients will be happy to avoid dexamethasone.

[Joakim_Von_And]

Ligefrem dejligt at være 40+